Invention Grant
- Patent Title: Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
-
Application No.: US16758124Application Date: 2018-10-16
-
Publication No.: US11613581B2Publication Date: 2023-03-28
- Inventor: Manoj Baburao Charati , Yoon-Chi Han , Madan Katragadda , Nicole Melissa Piché-Nicholas , Lawrence Nathan Tumey
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agency: Saul Ewing LLP
- International Application: PCT/IB2018/058013 WO 20181016
- International Announcement: WO2019/082020 WO 20190502
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K47/68 ; A61P35/00 ; C12N15/63 ; A61K39/00

Abstract:
The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
Public/Granted literature
- US20200283536A1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF Public/Granted day:2020-09-10
Information query